Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

ClinicalTrials.gov ID: NCT01235962

Public ClinicalTrials.gov record NCT01235962. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery.

Study identification

NCT ID
NCT01235962
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,538 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 29, 2010
Primary completion
Oct 14, 2015
Completion
Apr 14, 2019
Last update posted
Nov 22, 2020

2010 – 2019

United States locations

U.S. sites
69
U.S. states
28
U.S. cities
56
Facility City State ZIP Site status
Novartis Investigative Site Jonesboro Arkansas 72401
Novartis Investigative Site Antioch California 94531
Novartis Investigative Site Beverly Hills California 90211
Novartis Investigative Site Fresno California 93720
Novartis Investigative Site La Jolla California 92093
Novartis Investigative Site Los Angeles California 90033
Novartis Investigative Site Los Angeles California 90048-0750
Novartis Investigative Site Los Angeles California 90095
Novartis Investigative Site Oakland California 94611
Novartis Investigative Site Sacramento California 95825
Novartis Investigative Site San Francisco California 94115
Novartis Investigative Site South San Francisco California 94080
Novartis Investigative Site Stanford California 94305
Novartis Investigative Site Vallejo California 94589
Novartis Investigative Site Fort Collins Colorado 80528
Novartis Investigative Site Washington D.C. District of Columbia 20007
Novartis Investigative Site Fort Myers Florida 33916
Novartis Investigative Site Tampa Florida 33612
Novartis Investigative Site Athens Georgia 30607
Novartis Investigative Site Macon Georgia 31201
Novartis Investigative Site Chicago Illinois 60637
Novartis Investigative Site Indianapolis Indiana 46202
Novartis Investigative Site Iowa City Iowa 52242
Novartis Investigative Site Baltimore Maryland 21231
Novartis Investigative Site Boston Massachusetts 02114
Novartis Investigative Site Boston Massachusetts 02115
Novartis Investigative Site Boston Massachusetts 02215
Novartis Investigative Site Burlington Massachusetts 01805
Novartis Investigative Site Detroit Michigan 48201
Novartis Investigative Site Rochester Minnesota 55905
Novartis Investigative Site Saint Louis Park Minnesota 55416
Novartis Investigative Site St Louis Missouri 63110
Novartis Investigative Site Lincoln Nebraska 68510
Novartis Investigative Site Omaha Nebraska 68114
Novartis Investigative Site Omaha Nebraska 68118
Novartis Investigative Site Las Vegas Nevada 89169
Novartis Investigative Site Hackensack New Jersey 07601
Novartis Investigative Site Albany New York 12206
Novartis Investigative Site Buffalo New York 14263
Novartis Investigative Site New York New York 10003
Novartis Investigative Site New York New York 10021
Novartis Investigative Site New York New York 10065
Novartis Investigative Site Durham North Carolina 27710
Novartis Investigative Site Cincinnati Ohio 45242
Novartis Investigative Site Cleveland Ohio 44195
Novartis Investigative Site Columbus Ohio 43210
Novartis Investigative Site Portland Oregon 97213
Novartis Investigative Site Springfield Oregon 97477
Novartis Investigative Site Philadelphia Pennsylvania 19104
Novartis Investigative Site Philadelphia Pennsylvania 19106
Novartis Investigative Site Philadelphia Pennsylvania 19107
Novartis Investigative Site Philadelphia Pennsylvania 19111
Novartis Investigative Site Providence Rhode Island 02903
Novartis Investigative Site Providence Rhode Island 02906
Novartis Investigative Site Charleston South Carolina 29425
Novartis Investigative Site Chattanooga Tennessee 37404
Novartis Investigative Site Memphis Tennessee 38120
Novartis Investigative Site Nashville Tennessee 37203
Novartis Investigative Site Nashville Tennessee 37232
Novartis Investigative Site Bedford Texas 76022
Novartis Investigative Site Dallas Texas 75246
Novartis Investigative Site Houston Texas 77024
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site San Antonio Texas 78217
Novartis Investigative Site Tyler Texas 75702
Novartis Investigative Site Hampton Virginia 23666
Novartis Investigative Site Richmond Virginia 23230
Novartis Investigative Site Virginia Beach Virginia 23462
Novartis Investigative Site Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 243 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01235962, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01235962 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →